Samer Al Hadidi, Associate Professor at UT Southwestern Medical Center, shared a post on X:
“Treatment Refinement in Multiple Myeloma by Suzanne Lentzsch at ASH25.
Reasons why CAR-T should be positioned before BsAbs.”
Sridevi Rajeeve, Assistant Attending Physician of Myeloma and Cell Therapy Service at Memorial Sloan Kettering Cancer Center, shared this post, adding:
“Important reminder to continue offering CAR-T for eligible pts even in the era of (combination) bsAb, given faster immunologic recovery, better resistance patterns and durable efficacy following the one-time infusion of CAR-T.”
More posts featuring Samer Al Hadidi.